Predictive Oncology Inc. (NasdaqCM:POAI) acquired zPREDICTA, Inc. for $10 million on November 24, 2021. The consideration is payable in cash and is subject to working capital adjustments. Post-completion, Julia Kirshner, Chief Executive Officer of zPREDICTA will become President of Predictive Oncology's zPREDICTA division. The transaction is approved by the boards of Predictive Oncology and zPREDICTA. The transaction also received approval from shareholders of zPREDICTA. Martin R. Rosenbaum of Maslon LLP acted as legal advisor for Predictive Oncology while Stephanie Zeppa of Sheppard, Mullin, Richter & Hampton LLP acted as legal advisor for shareholders of zPREDICTA. Predictive Oncology Inc. (NasdaqCM:POAI) completed the acquisition of zPREDICTA, Inc. on November 24, 2021.